Merck & Co., Inc. $MRK Shares Sold by Rockland Trust Co.

Key Points

• Rockland Trust reduced its Merck stake by 8.4% in the second quarter, selling 44,914 shares and retaining 490,049 shares valued at about $63 million. Other institutional investors increased their positions, with institutions collectively owning 76.07% of MRK.
• Merck reported quarterly revenue of $16.61 billion, above estimates, while adjusted EPS of $0.13 beat expectations by $0.13; revenue rose 5.1% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $134.56.
• The company declared a quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a 2.6% yield. Meanwhile, insiders sold approximately 86,553 shares worth $11.2 million over the quarter.

Rockland Trust Co. reduced its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 8.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 490,049 shares of the company's stock after selling 44,914 shares during the period. Merck & Co., Inc. comprises approximately 2.5% of Rockland Trust Co.'s holdings, making the stock its 9th largest position. Rockland Trust Co.'s holdings in Merck & Co., Inc. were worth $62,971,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC grew its position in Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after purchasing an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC boosted its position in shares of Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock worth $2,590,000 after buying an additional 15,636 shares during the period. Diversify Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock worth $3,054,000 after buying an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock valued at $53,918,000 after buying an additional 359,356 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $128.61 on Friday. The firm has a market cap of $317.64 billion, a price-to-earnings ratio of 102.89, a P/E/G ratio of 5.53 and a beta of 0.19. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.05. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The business has a fifty day simple moving average of $123.98 and a 200 day simple moving average of $119.11.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the company posted $2.13 earnings per share. The business's quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on MRK shares. Morgan Stanley upped their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research report on Thursday, July 9th. Weiss Ratings cut Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Finally, BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $134.56.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company's stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 86,553 shares of company stock worth $11,177,945. Insiders own 0.17% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source